BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 11, Issue 11
  • This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (10544)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.
Item 
Count 
PDF548
WORD277
HTML5811
Figures (1-3)539
Tables (1-4)439
 Sum=7614
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse828
Download2102
 Sum=2930
Nov 15, 2019 (publication date) through Nov 5, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study
Copyright ©The Author(s) 2019.
World J Gastrointest Oncol. Nov 15, 2019; 11(11): 1065-1080
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1065
Table 1 Name of primers, location, and the sequence of microsatellite instability
SNPLocationPrimer sequence
BAT262p16p1 TGACTACTTTTGACTTCAGCC
p2 AACCATTCAACATTTTTAACCC
D2S1232p21-2p16p1 AAACAGGATGCCTGCCTTTA
p2 GGACTTTCCACCTATGGGAC
D5S3465q21-5q22p1 ACTCACTCTAGTGATAAATCGGG
p2 CAGATAAGACAGTATTACTAGTT
BAT254q12p1 TCGCCTCCAAGAATGTAAGT
p2 TCTGCATTTTAACTATGGCTC
D17S25017q11.2-17q12p1 GGAAGAATCAAATAGACAAT
p2 GCTGGCCATATATATATTTAAACC
SNP: Single nucleotide polymorphism.
Full Size Table
Table 2 Relationship between clinicopathological features and MutL homolog1/MutS homolog2 expression in 681 patients, n (%)
ObservationPositiveaNegativebTotalχ2P value
Gender
Male310 (80.10)77 (19.90)3870.2520.625
Female240 (81.63)54 (18.37)294
Age (yr)
≤5063 (88.73)8 (11.27)713.2400.072
>50487 (79.84)123 (20.16)610
Location in the colon
Left138 (82.14)30 (17.86)1684.7460.029
Right119 (72.12)46 (27.88)165
Location of tumor Colon257 (77.18)76 (22.82)3335.3950.025
Rectum293 (84.20)55 (15.80)348
Grade of differentiation
Poor28 (66.67)14 (33.33)425.7250.017
Well-moderate522 (81.69)117 (18.31)639
Tumor stage (TNM)
II324 (82.03)71 (17.97)3950.9640.327
III226 (79.02)60 (20.98)286
Tumor size (cm)
≤4210 (78.95)56 (21.05)2660.9270. 370
>4340 (81.93)75 (18.07)415
Lymphocytic infiltration
None or little336 (82.76)70 (17.24)4061.1950.332
Marked or moderate214 (75.76)61 (27.24)275
Mucin
Positive108 (73.97)38 (26.03)1465.5170.024
Negative442 (82.62)93 (17.38)535
Circumscribed margin
Negative482 (79.80)122 (20.20)6043.1840.090
Positive68 (88.31)9 (11.69)77
aMLH1/MSH2 positive;
bMLH1/MSH2 negative. MLH1: MutL homolog 1; MSH2: MutS homolog 2.
Full Size Table
Table 3 Prognostic factors for survival in univariate and multivariate analyses
ObservationUnivariate
Multivariate
PHR95%CIPHR95%CI
Model 1a
Gender
Male vs Female0.9320.9840.684-1.4170.9910.9980.685-1.454
Age/yr
≤50 vs >50< 0.0010.2880.189-0.4380.0250.5080.213-0.995
Location in the colon
Left vs Right0.7301.0860.678-1.7400.4401.2110.745-1.967
Location of tumor
Rectum vs Colon0.2321.3110.840-2.0470.0171.7951.111-2.902
Differentiation
Poor vs Well-moderate0.0020.4260.472-0.7340.9230.9720.542-1.741
Tumor stage
II vs III0.0340.6510.437-0.9680.0410.6010.321-0.932
Tumor size
<4 vs ≥4 cm0.6460.9210.647-1.3110.4210.8610.598-1.240
Lymphocytic infiltration
Positive vs Negative< 0.0012.2821.092-5.7560.0223.6651.207-7.128
Mucin
Positive vs Negative0.0012.3611.647-3.383< 0.0012.5121.714-4.682
Circumscribed margin
Positive vs Negative< 0.0013.9082.654-5.7550.0112.4741.433-4.270
MLH1/ MSH2
Positive vs Negative< 0.0013.7992.205-6.546< 0.0014.0642.241-7.369
Model 2b
Gender
Male vs Female0.7610.8960.441-1.8210.2070.6220.298-1.300
Age/yr
≤50 vs >50< 0.0010.1500.075-0.302< 0.0010.1310.063-0.271
MLH1/ MSH2
Positive vs Negative0.0144.8331.382-16.8990.0115.5831.478-21.092
Therapeutic regimen
Operation vs Operation + Chemotherapy0.1760.8210.520-1.2330.0630.9010.899-2.312
Model 3c
Gender
Male vs Female0.9640.9900.647-1.5170.7480.9320.607-1.432
Age/yr
≤50 vs >500.0020.4240.247-0.7280.0040.4460.258-0.769
MLH1/ MSH2
Positive vs Negative0.0411.6251.042-2.8030.0232.2891.270-4.125
Therapeutic regimen
Operation vs Operation + Chemotherapy0.0282.8911.209-6.372< 0.0014.0021.929-9.425
aAll 681 patients;
b395 Patients with stage II CRC;
c286 Patients with stage III CRC. HR: hazard ratio; CI: confidence interval; CRC: Colorectal cancer; MLH1: MutL homolog 1; MSH2: MutS homolog 2.
Full Size Table
Table 4 Predictive factors for survival in univariate and multivariate analyses
ObservationUnivariate
Multivariate
PHR95%CIPHR95%CI
Model 1a
MLH1/MSH2 negative
Operation vs Operation + Chemotherapy0.0981.0210.342-2.7410.1471.5630.481-4.441
MLH1/MSH2 positive
Operation vs Operation + Chemotherapy0.0811.8990.127-4.1140.0701.2670.212-5.052
Model 2b
MLH1/MSH2 negative
Operation vs Operation + Chemotherapy0.0014.3932.068-12.316< 0.0017.6602.974-15.883
MLH1/MSH2 positive
Operation vs Operation + Chemotherapy0.0632.0150.648-5.9970.0522.8170.223-6.671
a395 Patients with stage II CRC;
b286 Patients with stage III CRC. HR: hazard ratio; CI: confidence interval; MLH1: MutL homolog 1; MSH2: MutS homolog 2.
Full Size Table
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345